Clinical features and risk factors of lactic acidosis following long-term antiretroviral therapy: 4 Fatal cases

International Journal of STD and AIDS

Volumn 11, Issue 9, 2000, Pages 611-616

  Hofstede, H J M T ^a   De Marie, S ^b   Foudraine, N A ^c   Danner, S A ^d   Brinkman, K ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c National AIDS Therapy Evaluation Centre

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Adverse effects; HIV treatment; Lactic acidosis; Mitochondrial toxicity; Nucleoside analogue reverse transcriptase inhibitors; Risk factors

Indexed keywords

ANTIRETROVIRUS AGENT; BLEOMYCIN; DIDANOSINE; HYDROXYUREA; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; RIBOFLAVIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VINBLASTINE; ZALCITABINE;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMORBIDITY; FATALITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LACTIC ACIDOSIS; LONG TERM CARE; MALE; MITOCHONDRION; NEUROPATHY; PRIORITY JOURNAL; RISK FACTOR; SCREENING TEST; TACHYPNEA; TREATMENT FAILURE;

ACIDOSIS, LACTIC; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FATAL OUTCOME; FEMALE; HIV INFECTIONS; HUMANS; MALE; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS;

EID: 0033824578     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462001916498     Document Type: Article

References (28)

1. Type B lactic acidosis in an AIDS patient treated with zidovudine
2. Hepatomegaly with severe steatosis in HIV-seropositive patients
3. A new syndrome of hepatomegaly with severe steatosis in HIV seropositive patients
4. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: Report of two patients and review of the literature
5. Lactic acidosis complicating the acquired immunodeficiency syndrome
6. Fulminant hepatic failure associated with 2'3'-dideoxyinosine (ddI)
7. Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy
8. Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: A case report
9. Cyclic vomiting syndrome and mitochondrial DNA mutations
10. Riboflavine and severe lactic acidosis
11. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway
12. Mitochondrial toxicity of antiviral drugs
13. Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine
14. Severe toxicity of fialuridine (FIAU)
15. Mitochondrial myopathy associated with chronic zidovudine therapy in AIDS
16. Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships
17. Zidovudine. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy
18. Stavudine: A review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection
19. Didanosine. An update on its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV disease
20. Zalcitabine. An update of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of HIV infection
21. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy
22. The intracellular phosphorylation of (-)-2'-deoxy-3'-thiacytidine (3TC) and the incorporation of 3TC 5'-monophosphate into DNA by HIV-1 reverse transcriptase and human DNA polymerase gamma
23. 2',3'-dideoxycytidine metabolism in a new drug-resistant cell line
24. Determination of the blood actate: Pyruvate ratio as a noninvasive test for the diagnosis of zidovudine myopathy
25. Clinical aspects of mitochondrial disorders
26. Riboflavin to treat nucleoside analogue-induced lactic acidosis
27. Therapy of mitochondrial disorders
28. Treatment of mitochondrial disease